Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)…
Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients
September 09, 2025 13:19 ET | Source: Booking Health Langenfeld, Germany, Sept.…
Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib…
KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients
RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
July 25, 2025 16:05 ET | Source: atai Life Sciences Initial results…
